Stability and sterility of recombinant tissue plasminogen activator at −30°C Journal Articles

abstract

• We assessed whether frozen recombinant tissue plasminogen activator (rt-PA) remains stable and sterile for up to 22 weeks at -30 degrees C. Our findings confirm that rt-PA is a cost-effective alternative to urokinase for restoring patency to occluded central venous catheters.

authors

• Wiernikowski, John T
• Crowther, Mark
• Clase, Catherine
• Ingram, Alistair
• Andrew, Maureen
• Chan, Anthony

status

• published 

publication date

• June 2000

has subject area

• 11 Medical and Health Sciences (FoR)
• Catheterization, Central Venous (MeSH)
• Catheters, Indwelling (MeSH)
• Cost-Benefit Analysis (MeSH)
• Drug Contamination (MeSH)
• Drug Stability (MeSH)
• Freezing (MeSH)
• General & Internal Medicine (Science Metrix)
• Humans (MeSH)
• Plasminogen Activators (MeSH)
• Recombinant Proteins (MeSH)
• Thrombolytic Therapy (MeSH)
• Thrombosis (MeSH)
• Time Factors (MeSH)
• Tissue Plasminogen Activator (MeSH)
• Urokinase-Type Plasminogen Activator (MeSH)

published in

• The Lancet  Journal

keywords

• Catheterization, Central Venous
• Catheters, Indwelling
• Cost-Benefit Analysis
• Drug Contamination
• Drug Stability
• Freezing
• Humans
• Plasminogen Activators
• Recombinant Proteins
• Thrombolytic Therapy
• Thrombosis
• Time Factors
• Tissue Plasminogen Activator
• Urokinase-Type Plasminogen Activator

Digital Object Identifier (DOI)

• 10.1016/s0140-6736(00)02411-9

PubMed ID

• 10881901

start page

• 2221

end page

• 2221

volume

• 355

issue

• 9222